Generic Name: belinostat

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Chemotherapy Medications

Company: Spectrum

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Beleodaq is an HDAC inhibitor approved for relapsed or refractory peripheral T-cell lymphoma.

General Info

Beleodaq is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.


Dosing Info: Beleodaq is administered by intravenous infusion. It is usually given on the first five days of a 21-day cycle until disease progression or unacceptable side effects occur.

Side Effects

Common side effects include nausea, fatigue, fever and vomiting. Beleodaq can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential severe side effects include liver problems and tumor lysis syndrome, a reaction that can occur when cancer cells die suddenly. Beleodaq may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 29, 2018